Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Economic Development topic
No spam. Unsubscribe anytime.
Economic development update spotlights local biotech firm Elucia
Summary
City economic development remarks highlighted Gaithersburg's biotech cluster and described Elucia's recent financial turnaround, a sale of a product line to Boston Scientific, and ongoing marketing of additional products.
During the March 16 meeting the council received an economic development update highlighting Gaithersburg as a regional biotech center and briefly spotlighting Elucia, a regenerative medicine company operating in the city.
The presenter noted the city hosts substantial lab space and named companies including AstraZeneca, Novavax and Emergent as part of the local ecosystem. The presenter described Elucia as occupying roughly 26,000 square feet at 21st Field Road (as stated in the transcript) and said the company reported a turnaround to approximately $53.4 million in net income over the last 12 months compared with a prior-year loss reported in the remarks. The presenter also said Elucia sold a product line (an implantable pouch that emits antibiotics) to Boston Scientific for $88 million and is marketing an additional product line (Simploderm) to accelerate commercialization of a device focused on preventing infection after breast reconstruction surgeries.
Remarks thanked CEO Randy Mills and investors for continued investment in the city. No formal city action was taken on the company update; the remarks were informational.
